Is PROTHENA CORP PUBLIC LTD CO (PRTA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.6% / 30% | 59.6% / 30% | 0.0% / 30% | 146.0% / 5% | ✗ NOT HALAL |
| DJIM | 1.6% / 33% | 59.6% / 33% | 0.0% / 33% | 146.0% / 5% | ✗ NOT HALAL |
| MSCI | 2.6% / 33% | 94.1% / 33% | 0.0% / 33% | 146.0% / 5% | ✗ NOT HALAL |
| S&P | 1.6% / 33% | 59.6% / 33% | 0.0% / 33% | 146.0% / 5% | ✗ NOT HALAL |
| FTSE | 2.6% / 33% | 94.1% / 33% | 0.0% / 50% | 146.0% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -129576.2% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -63.6% | |
| Return on Assets (ROA) | -26.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$164M |
| Free Cash Flow | -$164M |
| Total Debt | $8M |
| Debt-to-Equity | 3.0 |
| Current Ratio | 7.7 |
| Total Assets | $327M |
Price & Trading
| Last Close | $9.52 |
| 50-Day MA | $9.17 |
| 200-Day MA | $8.79 |
| Avg Volume | 507K |
| Beta | -0.3 |
|
52-Week Range
$4.32
| |
About PROTHENA CORP PUBLIC LTD CO (PRTA)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PROTHENA CORP PUBLIC LTD CO (PRTA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PROTHENA CORP PUBLIC LTD CO is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PROTHENA CORP PUBLIC LTD CO's debt ratio?
PROTHENA CORP PUBLIC LTD CO's debt ratio is 1.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.6%.
What are PROTHENA CORP PUBLIC LTD CO's key financial metrics?
PROTHENA CORP PUBLIC LTD CO has a market capitalization of $498M, and revenue of $10M. Return on equity stands at -63.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.